header icons.png

Michael Pazianas, MD

Publications (peer reviewed)

 

  1. Pazianas M. RE: One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study. Calcif Tissue Int. 2023 May;112(5):628-629.

  2. Pazianas M. Atorvastatin reduces zoledronic acid-induced osteonecrosis of the jaws of rats. Bone. 2022 Sep 20:116561.

  3. Pazianas M. Engineered osteoclasts resorb necrotic alveolar bone in anti-RANKL antibody-treated mice. Bone. 2021 Dec:153:116173.

  4. Pazianas M. The role of bone biopsy in the management of CKD-MBD and Osteoporosis. Calcif Tissue Int. 2021 Jul;109(1):110-11. 

  5. Pazianas M. NE-58025: A Bisphosphonate with a low hydroxyapatite binding affinity. JBMR Plus. 2021 May 7;5(8):e10502. 

  6. Pazianas M, Miller P.  Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease (CKD-MBD) and the scientific grounds on the Use of exogenous PTH in its management. J Bone Metab 2020;27(1):1-13.

  7. Pazianas M. Dietary calcium intake and bone loss over 6 years in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2019; 104(9): 3609.

  8. Pazianas M. FGF-23 in untreated nephrotic syndrome and effects of the renin-angiotensin-aldosterone system (RAAS).  Nephrology (Carlton). 2019; 24(2): 273.    

  9. Pazianas M. Effectiveness of calcium and vitamin D supplementation in osteoporosis. Ann N Y Acad Sci. 2018 Dec; 1433(1): 5-6.

  10. Garriga C, Pazianas M, Hawley S, Delmestri A, Prieto-Alhambra D, Cooper C, Judge A. Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study. Ann N Y Acad Sci. 2018 Mar; 1415(1): 34-46.

  11. Shah NP, Nayee S, Pazianas M, Hughes F, Sproat C.  Beyond ONJ - A review of the potential uses of bisphosphonates in dentistry. Br Dent J. 2017 May 12; 222(9): 727-730. 

  12. Paziana K, Pazianas M.  Calcium supplements controversy in osteoporosis: a physiological mechanism supporting cardiovascular adverse effects.  Endocrine  2015; 48(3): 776-78.

  13. Shah N, Katsarelis H, Pazianas M, Dhariwal DK.  ONJ: Periodontal Disease, Implants and Extractions where do we currently stand?  Dent Update. 2015 Nov; 42(9): 878-89. 

  14. Pazianas M, Abrahamsen B. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.  Osteoporos Int. 2014 Nov; 25(11): 2669

  15. Pazianas M, van der Geest S, Miller P.  Bisphosphonates and bone quality.  BoneKey Rep . 2014 May 7; 3: 529 eCollection 2014. 

  16. Suresh E, Pazianas M, Abrahamsen B. Safety issues with bisphosphonate therapy  for osteoporosis.  Rheumatology (Oxford). 2014 Jan;53(1):19-31.

  17. Pazianas M, Abrahamsen B, Ferrari S, Russell RGG. Eliminating fasting in oral administration of bisphosphonates.  Ther Clin Risk Manag. 2013: 9; 395-402.

  18. Abrahamsen B, Pazianas M, Russell RG. Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted.  BMJ. 2013 Mar 12; 346: f1514.

  19. Pazianas M, Clark EM, Eiken PA, Brixen K, Abrahamsen B. Inflammatory Eye Reactions in Patients treated with bisphosphonates and other osteoporosis medications- Cohort analysis using a national prescription database.  J Bone Miner Res. 2013 Mar; 28(3): 455-63.  

  20. Pazianas M. Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class? JAMA Intern Med. 2013 Jan 14; 173(1): 79-80.

  21. Pazianas M, Abrahamsen B, Russell RGG. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy. A register-based cohort study using the US MarketScan claims databases.  Osteoporos Int. 2012 Dec; 23(12): 2873-84.  

  22. Pazianas M, Russell RGG. Potential Therapeutic effects of oral bisphosphonates on the intestine.  Ann N Y Acad Sci. 2011 Dec; 1240: E19-25.  

  23. Pazianas M, Abrahamsen B, Eiken PA, Eastell R,  Russell RGG. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate  Danish National Register Based Cohort Study.  Osteoporos Int. 2012 Nov; 23(11): 2693-701.  

  24. Abrahamsen B, Pazianas M, Eiken P, Russell RGG, Eastell R. Esophageal and gastric cancer incidence and mortality in alendronate users.  J Bone Miner Res. 2012; 27(3): 679-86.

  25. Pazianas M. Osteonecrosis of the jaw and the role of macrophages.  J Natl Cancer Inst. 2011 Feb 2; 103(3): 232-40. 

  26. Prieto-Alhambra P, Judge A, Pazianas M. High-dose vitamin D supplementation and suppression of the renin-angiotensin system: an alternative explanation for the observed increase in falls rate.  JAMA 2010; 304(8): 854-57.

  27. Pazianas M. Clodronate liposomes for depletion of Tumor-associated macrophages in classic Hodgkin's lymphoma.  N Engl J Med 2010 Jun 3; 362(22): 2135-36. 

  28. Pazianas M, Cooper C, Wang Y,  LangeLJ, Russell RGG. Atrial fibrillation and the use of oral bisphosphonates.  Ther Clin Risk Manag. 2010 Jul 21; 6: 325-43.

  29. Pazianas M, Cooper C, Ebetino FH, Russell RGG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.  Ther Clin Risk Manag. 2010; 6: 325-43.  (Invited article)

  30. Pazianas M. Association between the use of serotonin receptor 2A-blocking antidepressants and joint disorders.  Arthritis Care Res (Hoboken). 2010; 62(6): 902

  31. Pazianas M, Epstein S, Zaidi M. Evaluating the efficacy of bisphosphonates. Rev Recent Clin Trials. 2009; 4: 122-30.

  32. Pazianas M. Calcific Aortic Stenosis.  N Engl J Med 2009 Jan 1; 360(1): 85-6.

  33. Pazianas M, Blumentals WA, Miller P. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker.  Osteoporos Int 2008;19: 773-79.  

  34. Pazianas M,  Miller P, Blumentals WA, Bernal M, Kothawala P.  Prevalence, risk factors and clinical characteristics of osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients treated with bisphosphonates.  Clin Ther 2007; 29: 1548-58. 

  35. Compher C, Pazianas M., Benedict S, Brown J.C, Kinosian B, Hise M. Systemic inflammatory mediators in Calcium and Phosphate homeostasis.  JPEN J Parenter Enteral Nutr 2007; 31: 142-47.

  36. Pazianas M, Compher C, Schiavone-Gatto  P, Nierman E, Kinosian B.  Intestinal failure-associated osteoporosis and response to Teriparatide.  Nutr Clin Pract 2006; 21: 605-9.  

  37. Lichtenstein G.R, Sands B.E, Pazianas M.  Prevention and Treatment of osteoperosis in Inflammatory Bowel Disease.  Inflammatory Bowel Disease 2006; 12: 796–812.

  38. Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR.  The Effect of anti-TNFa therapy on spinal bone mineral density in patients with Crohn’s disease.  Ann. N. Y. Acad. Sci. 2006; 1068: 543–56.

  39. Pazianas M. Relationship between serum 25-HO D and pulmonary function in the NHANES III.  Chest  28 December 2005  http://www.chestjournal.org/cgi/eletters/128/6/3792#841

  40.  Wang JH, Pazianas M, Fraser WD, Harris F, Eastwood JB.  Acute renal failure & hypercalcaemia in a man from Guyana: what is the link?  Nephrol Dial Transpl 2005; 20: 1505-8.

  41.  Campbell MS, Lichtenstein G.R,  Rhim AD, Pazianas M, Faust T.  Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis.  Liver Int 2005; 25: 311-16.

  42.  Pazianas M, Butcher GP, Subhani J, Finch PJ, Ang L, Collins C, Heaney RP, Zaidi M, Maxwell JD. Calcium absorption and bone mineral density in celiacs after long term treatment with gluten-free diet and adequate calcium intake.  Osteoporos Int 2005; 16: 56-63.

  43.  Pazianas M, Subhani J, Finch, Ang L, Maxwell JD. Bone mineral density and efferent loop duodenal Vitamin D Receptor concentration after Billroth II (Polya) gastrectomy.  Calcified Tissue Int 2003; 72: 485-90.

  44. Verma A, Maxwell JD, Ang L, Davis T, Hodges S, Northfield TC, Zaidi M, Pazianas M. Ursodeoxycholic acid enhances  calcium absorption with primary billiary cirrhosis.  Osteoporos Intl 2002; 13: 677-82.

  45.  Pazianas M and Zaidi M. Two underlying diseases causing hypercalcaemia?  Nephrol Dial Transpl 2002; 17: 1141-52.

  46.  Rado J, Rodin A, Pazianas M, Nussey SS. Reduced bone mineral density after surgical treatment obesity.  Int J Obesity 1999; 23: 361-65.

  47.  Patel S, Pazianas M, Tobias J, Chambers TJ, Fox S, Chow J. Early effects of hormone replacement  therapy on bone.  Bone 1999; 24: 245-48.

  48.  Shankar VS, Simon B, Bax CMR, Pazianas M, Moonga, S, Adebanjo OA, Zaidi M Effects of electromagnetic stimulation on the functional responsiveness of isolated rat osteoclasts.  J Cell Physiol 1998; 176: 537-44.

  49.  Paton NIJ, Macallan DC, Griffin GE,  Pazianas M. Bone mineral density in patients with HIV infection.  Calcified Tissue Int 1997; 61: 30-32.

  50.  Tobias  JH, Dalzell N, Pazianas M, Chambers TJ.  The effect of cyclical etidronate on bone loss in early postmenopausal women with spinal osteopenia. Brit J Rheumatol  1997; 37: 612-3.

  51.  Paton NIJ, Macallan DC, Jebb SA, Noble C, Baldwin C, Pazianas M, Griffin GE. Longitudinal study of changes in body composition measured with a variety of methods in patients with AIDS.  J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 119-27.

  52.  Zaidi M, Shankar VS, Adebanjo OA, Lai AF, Pazianas M, Sunavala G, Spielman AI, Rifkin BR.  Regulation of extracellular Ca2+ sensing in rat osteoclasts by femtomolar calcitonin concentrations.  Am J Physiol 1996; 271: F637-44.

  53.  Adebanjo OA, Shankar VS, Pazianas M, Zaidi A, Simon BJ, Lai FA, Huang CL-H, Zaidi M.  Extracellularly applied ruthenium red and cADP ribose elevate cytosolic Ca2+ sensing in isolated rat osteoclasts.  Am J Physiol 1996; 270: F469-75.

  54. Paton NIJ, Macallan DC, Jebb SA, Noble C, Pazianas M, Griffin GE. Dual-energy X-ray absorpiometry results differ between machines.  Lancet 1995; 346: 899-900.

  55. Zaidi M, Shankar VS, Tunwell R, Adebanjo OA, Mackrill J, Pazianas M, O'Connell D, Simon BJ, Rifkin BR, Venkitaraman A, Huang CL-H, Lai AF. A ryanodine receptor-like molecule expressed in the osteoclast plasma membrane functions in extracellular Ca2+ sensing.  J Clin  Invest 1995; 96: 1582-90.

  56. Shankar VS, Pazianas M, Huang CL-H, Simon B, Adebanjo O, Zaidi M. Caffeine modulates Ca2+ receptor activation in isolated rat osteoclasts and induces intracellular Ca2+ release.  Am J Physiol 1995; 268: F447-54.

  57. Pazianas M, Adebanjo OA, Shankar VS, James SY, Colston KW, Maxwell JD,  Zaidi M. Extracellular cation sensing by the enterocytes: prediction of a novel divalent cation "receptor”.  Biochem Biophys Res Commun 1995; 210: 948-53.

  58. Pazianas M, Ciacci C, Eastwood JB, MacRae KD, Phillips ME. Long term oral calcitriol in patients on chronic haemodialysis.  J Nephrol 1995; 8: 45-52.

  59. Shankar VS, Huang CL-H, Adebanjo OA, Simon B, Alam ASMT, Moonga BS, Pazianas M, Scott RH, Zaidi M. Effect of membrane potential on surface Ca2+ receptor activation in rat osteoclasts.  J Cell Physiol 1995; 162: 1-8.

  60. Zaidi M, Shankar VS, Huang CL-H, Pazianas M. Molecular mechanisms of calcitonin action.  Endocrine 1994; 2: 459-67.

  61. Adebanjo 0A, Pazianas M, Zaidi A, Shankar VS, Bascal ZA, Dacke CG, Huang CL-H, Zaidi M. Quantitative studies on the effects of prostacyclin on freshly isolated rat osteoclasts in culture.  J Endocrinol 1994; 143: 375-81.

  62. Eastwood JB, Zaidi M, Maxwell JD, Wing AJ, Pazianas M. Tuberculosis as primary renal diagnosis in end-stage renal disease.  J Nephrol 1994; 7: 290-93.

  63. Shankar VS, Huang CL-H, Adebanjo OA, Pazianas M, Zaidi M. Calcium influx and release in isolated rat osteoclasts.  Exp Physiol 1994; 79: 537-45.

  64. Zaidi M, Bax BE, Shankar VS, Moonga BS, Simon B, Alam ASMT, Gaines Das RE, Pazianas M, Huang CL-H. Dimensional analysis of osteoclastic bone resorption arm measurement of biologically active calcitonin.  Exp Physiol 1994; 79: 387-99.

  65. Adebanjo OA, Shankar VS, Pazianas M, Zaidi A, Simon B, Huang CL-H, Zaidi M. Modulation of the osteoclast Ca2+ receptor by extracellular protons.  Possible linkage between Ca2+ sensing and extracellular acidification.  Biochem Biophys Res Commun 1994; 199: 742-47.

  66. Nussey SS, Hyer SJ, Brada M, Leiper AD, Pazianas M. Bone mineralization after treatment of growth hormone deficiency in survivors of childhood malignancy.  Acta Paediatr 1993; 83 (Suppl 399): 9-14.

  67. Zaidi M, Moonga BS, Huang CL-H, Alam ASMT, Shankar VS, Pazianas M, Datta HK, Rifkin BR. The effect of tetracyclines on quantitative measures of osteoclast morphology.  Biosci Rep 1993; 13: 175-82.

  68. Bax BE, Shankar VS, Bax CMR, Alam ASMT, Zara SJ, Pazianas M, Huang CL-H, Zaidi M. Functional consequences of the interaction of Ni2+ with the osteoclast Ca2+ receptor.  Exp Physiol 1993; 78: 517-30.

  69. Zaidi M, Shankar VS, Bax CMR, Bax BE, Bevis PJR, Pazianas M, Alam ASMT, Huang CL-H.  Linkage of extracellular and intracellular control of cytosolic Ca2+ in rat osteoclasts in the presence of thapsigargin. J Bone Mine Res 1993; 8: 961-67.

  70. Pazianas M, Zaidi M, Huang CL-H, Moonga BS, Shankar VS. Voltage-sensitivity of the osteoclast calcium receptor.  Biochem Biophys Res Commun 1993; 192: 1100-5.

  71. Moonga BS, Pazianas M, Alam ASMT, Shankar VS, Huang CL-H, Zaidi M. Stimulation of Gs-like protein in the osteoclast inhibits bone resorption but enhances tartrate-resistant acid phosphatase secretion.  Biochem Biophys Res Commun 1993; 190: 496-501.

  72. Shankar VS, Bax CR, Bax BE, Alam ASMT, Pazianas M, Huang CL-H, Zaidi M. Activation of the Ca2+ 'receptor’ on the osteoclast by Ni2+ elicits cytosolic Ca2+ signals: evidence for receptor activation and inactivation, intracellular Ca2+ redistribution and divalent cation modulation.  J Cell Physiol 1993; 155: 124-33.

  73. Zaidi M, Pazianas M, Shankar VS, Bax CMR, Bax BE, Bevis PJR, Stevens CR, Huang CL-H, Blake DR, Moonga BS, Alam ASMT. Osteoclast function and its control.  Exp Physiol 1993; 78: 721-40.

  74. Pazianas M, Lyritis G, Zaidi M.  Pharmakeutikes epidrasis ston metabolism ton oston.  Ostoun (Athens) 1993; 4: 129-43.

  75. Zaidi M, Alam ASMT, Bax BE, Shankar VS, Bax CMR, Gill JS, Pazianas M, Huang CL-H, Sahinoglu T, Stevens CR, Blake DR. Role of endothelial cell in osteoclast control: new perspectives.  Bone 1993; 14: 97-102.

  76. Zaidi M, Alam ASMT, Shankar VS, Pazianas M, Bax CMR, Bax BE, Moonga BS, Bevis PJR, Stevens CR, Blake DR, Huang CL-H. Cellular biology of bone resorption.  Biol Rev Camb Philos Soc 1993; 68: 197-264.

  77. Zaidi M, Alam ASMT, Huang CL-H, Pazianas M, Bax CMR, Bax BE, Moonga BS, Bevis PJR, Shankar VS. Extracellular Ca2+ sensing by the osteoclast.  Cell Calcium 1993; 14: 271-7.

  78. Zaidi M, Shankar VS, Huang CL-H, Pazianas M, Bloom SR. Amylin in bone conservation.  Trends Endocrin Met 1993; 5: 295-99.

  79. McMillan TM, Freemont AJ, Herxheimer A, Taylor AP, Denton J, Pazianas M, Eastwood JB. Camelford water poisoning accident: serial neurophysiological assessments and further observations on bone aluminum.  Hum Exp Toxicol 1993; 12: 37-42.

  80. Zaidi M, Alam ASMT, Shankar VS, Fairburn K, Moonga BS, Huang CL-H, Panetta J, Blake DR, Pazianas M. Inhibitors of bone resorption and indications for therapy.  Curr Opin Ther Patents 1992; 2: 1517-38.

  81. Zaidi M, Alam ASMT, Shankar VS, Bax BE, Moonga BS, Bevis PJR, Pazianas M, Huang CL-H. A quantitative description of components of in vitro morphometric change in the rat osteoclast model: relationships with cellular function.  Eur Biophys J 1992; 21: 349-55.

  82. Zaidi M, Shankar VS, Alam ASMT, Moonga BS, Pazianas M, Huang CL-H. Evidence that a ryanodine receptor triggers signal transduction in the osteoclast.  Biochem Biophys Res Commun 1992; 188: 1332-36.

  83. Alam ASMT, Bax CMR, Shankar VS, Bax BE, Bevis PJR, Huang CL-H, Moonga BS, Pazianas M, Zaidi M. Further studies on the mode of action of calcitonin on isolated rat osteoclasts.  Pharmacological evidence for a second site mediating [Ca2+]i mobilization and cell retraction.  J Endocrinol 1992; 136: 7-15.

  84. Shankar VS, Alam ASMT, Bax CMR, Bax BE, Pazianas M, Huang C.L-H, Zaidi M. Activation and inactivation of the osteoclast Ca2+ receptor by the trivalent cation La3+.  Biochem Biophys Res Commun 1992; 187: 907-12.

  85. Pazianas M, Phillips ME, MacRae KD, Eastwood JB. Identification of risk factors for radiographic hyperparathyroidism in 422 patients with end-stage renal disease: development of a clinical predictive index.  Nephrol Dial Transpl 1992; 7: 1098-1105.

  86. Pazianas M, Eastwood JB, MacRae KJ, Phillips ME. Racial origin and primary renal diagnosis in patients with end-stage renal disease.  Nephrol Dial Transpl 1991; 6: 931-5.

  87. Sethi D, Morgan TCN, Brown EA, Cary NRB, Erhardt CC, Pazianas M, Maini RN, Woodrow DF, Gower PE. Dialysis arthropathy: A clinical, biochemical, radiological ad histological study of 36 patients.  Q J Med 1990; 77: 1061-82.

  88. Eastwood JB, Levin GE, Pazianas M, Taylor AP, Denton J. Freemont AJ. Aluminum deposition in bone after accidental contamination of a public drinking water supply.  Lancet 1990; 336: 462-4.

  89. Maher ER, Pazianas M, Curtis JR. Calcific aortic stenosis: a complication of chronic uraemia.  Nephron 1987; 47: 119-22.

    Editorials/Invited Articles 

  90. Pazianas M, Miller P. Calcium and Phosphate Homeostasis and the Development of Osteoporosis and CKD-MBD. N Engl J Med – In preparation. 

  91. Pazianas M, Miller P.  The Rationale for Intermittent Administration of PTH in the Management of Mineral and Bone Disorder of Chronic Kidney Disease (CKD-MBD). J Nephrol. 2023. May 12.  Online ahead of print.

  92. Pazianas M, Miller PD. Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics. Am J Kidney Dis. 2021 Oct;78(4):582-589. 

  93. Pazianas M, Miller PD.  The CKD-MBD syndrome: hysteresis in PTH involvement and PTH administration for its management.  J Bone Miner Res. 2020;35(10):2313-17.     

  94. Pazianas M. Bones, Heart, and the new anabolic agent romosozumab.  Postgrad Med J. 2019; 95(1128): 521-23.

  95. Pazianas M, Abrahamsen B. Does bisphosphonate treatment reduce the risk of future cancer? Chin Clin Oncol. 2019; 8(S1):S3.

  96. Pazianas M. Oestrogens and ageing from the skeletal perspective.  Postgrad Med J. 2017 Mar; 93(1097): 113-14.

  97. Pazianas M, Abrahamsen B. Osteoporosis Treatment: Bisphosphonates reign to continue for a few more years, at least?.  Ann. N. Y. Acad. Sci. 2016 Jul; 1376(10): 5-13.

  98. Pazianas M. The Anabolic effects of PTH and the “Anabolic Window”.  Trends Endocrinol Metab. 2015 Mar; 26(3): 111-13.

  99. Katsarelis H, Shah N, Dhariwal DK, Pazianas M.  Infection and Medication Related Osteonecrosis of the Jaw.  J Dent Res. 2015; 94(4): 534-39.

  100. Pazianas M, Kim SM, Yuen T, Sun L, Epstein S, Zaidi M. Questioning the association between bisphosphonates and atypical femoral fractures.  Ann. N. Y. Acad. Sci. 2015 Jan; 1335(1 ):1-9.

  101. Pazianas M, Smith R. Drug-associated atypical femoral fractures (DaAFF): Balancing the facts.  J. Clin. Endocrinol. Metab.  2014 Jul; 99(7): 2340-42. 

  102. Pazianas M.  Osteonecrosis of the Jaw associated with antiresorptives: more evidence on the role of infection.  IBMS BoneKEy 2013 :10: 441(1-2).

  103. Pazianas M and Abrahamsen B. Safety of Bisphosphonates.  Bone 2011; 49(1): 103-10.

  104. Pazianas M, Compston J, Huang CL-H.  Atrial fibrillation and bisphosphonate therapy.  J Bone Miner Res.  2010; 25: 2-10.

  105. Pazianas M, Russell RGG, Fogelman I. Osteonecrosis of the Jaw (ONJ). More heat than light.  J Nucl Med. 2009; 50: 6-7.

  106. Pazianas M, Zaidi M. Renal Osteodystrophy.  Facts and prospects.  Hellenic Nephrology 1993; 5: 600-1.

  107. Colston K, Pazianas M. Primary hyperparathyroidism and 1,25-dihydroxyvitamin D.  Lancet 1991; 337: 768-69.

    Chapters 

  108. Miller P, Pazianas M. Bones and the Kidney. In: Oxford handbook of Endocrinology and Diabetes. Eds. J. Wass & K Owen. Oxford University Press. 2021.

  109.  Se-Min Kim S-M, Pazianas M, Yuen T, Aaron R, Zaidi M. Metabolic Bone Disease. In Orthopedic Basic Science: Foundations of Clinical Practice Chapter 25. Ed. Roy Aaron. Wolters Kluwer 2020.

  110.  Se-Min Kim S-M, Pazianas M, Yuen T, Aaron R, Zaidi M. Metabolic Bone Disease for Orthopedic Surgeons. American Academy of Orthopaedic Surgeons (AAOS) digital publication. 2018.

  111.  Russell RGG, Tsipra M, Ebetino FH, Pazianas M. Antiresorptives. In:  The duration and safety of osteoporosis treatment: Anabolic and antiresorptive therapy. Eds. Silverman & Abrahamsen B. Springer 2016.

  112.  Kim Se-Min, Epstein S, Yuen T, Pazianas M, Sun Li, Murphy B, Zaidi M. Metabolic bone disease following organ transplantation. In Diagnosis and Management of Hip Disease – Biological bases of clinical care, chapter 10. Editor Roy K. Aaron. Springer International Publishing 2015; pp185-206.

  113.  Zaidi M,  Pazianas M.  Osteoporosis due to hormonal withdrawal: Common mistakes.  Chapter 22

  114.  Pazianas M.  Zaidi M.  Osteomalacia: A cause of bisphosphonate failure.  Chapter 23.

  115.  Zaidi M,  Pazianas M.  Unusual manifestations of Paget’s disease of bone. Chapter 24.

  116.  Pazianas M.  Zaidi M.  Solid Organ transplantation, Chronic renal impairment, and Skeletal complications. Chapter 25.  In: A case-based Guide to Clinical Endocrinology.  Metabolic Bone Diseases.  Part IV:  Ed. Davies T.  Humana Press 2008, pages: 203- 230.

  117.  Pignolo JR, Schwab E, Pazianas M.  Osteoporosis.  In: Geriatric Secrets Third edition.  Eds. Forceia MA, Lavizo-Mourey, Schwab E. Hanley & Belfus Inc, Philadelphia 2004; 7: 80-86.

  118.  Eastwood JB, Pazianas M. Renal bone disease.  In: Rheumatology.  Eds.  Hochiberg MC, Silman AJ, Smolen JS, Weinblant ME, Weisman MH. Mosby – Elsevier Science 2003 vol. II; 202: 2133-38.

  119.  Adebanjo OA, Schwab E, Sun L, Pazianas M, Moonga B, Zaidi M.  Molecular pharmacology of antiresorptive therapy for osteoporosis. In: Advances in Organ Biology /Molecular and Cellular Biology of Bone  Part 5C.  Eds M. Zaidi,  O.A. Adebanjo, C.L.H Huang.  Elsevier 1998.

  120.  Zaidi M, Pazianas M, Shankar VS, Huang CL-H. Cell biology of calcitonin action.  In: Principles of Medical Biology.  Eds. EE Bittar, N Bittar.  JAI Press Inc., Greenwich, Connecticut, USA. 1997; 601-16.

  121.  Eastwood JB, Pazianas M. Calcium and phosphate metabolism.  In: Nephrology. Eds. R.Willkinson, R. Jamison.  Chapman and Hall, London (Publishers) 1997; pp. 358-68.

  122.  Zaidi M, Pazianas M, Shankar VS, Adebanjo OA, Zaidi A, Huang CL-H. The role of endothelin in skeletal homeostasis.  In: Endothelin: Role in Health and Disease.  Ed. Gulati A. Harwood Academic Publishers Gmbh (Amsterdam) 1995; pp. 361-7.

  123.  Zaidi M, Alam ASMT, Bax CR, Shankar VS, Bevis PJR, Huang CL-H, Pazianas M, Moonga BS.  Cytosolic free calcium measurements in single cells using calcium sensitive fluorochromes.  In: Methods in Molecular Biology. Volume 27, chapter 20. Eds, Graham JM, Higgins JA. Humana Press Inc. (New Jersey) 1994; pp.279-93.

  124.  Eastwood JB, Pazianas M, Maxwell JD, Wing AJ. Tuberculosis as a cause of end-stage renal disease in countries reporting to EDTA Registry.  In: Current Therapy in Nephrology. Eds. VE Andreucci, A. Dal Canton.  Wichting Editore, Milano, Italy, 1993; 3-9.

  125.  Eastwood JB, Pazianas M, Moriniere PJ, Fournier A. Indications for surgery in secondary hyperparathyroidism.  In: Surgical Endocrinology.  Eds. Lynn JA, Bloom SR. Butterworth-Heinemann, London, 1993; 30: 362-9.

  126.  Pazianas M, Eastwood JB, MacRae KD, Phillips ME. Hyperparathyroidism at the time of initiation of renal replacement therapy. In: Contemporary Management of Renal Failure. Eds. Man N-K, Botella J, Zucchelli P. Nose Y, ICAOT Press, Cleveland, Ohio, USA, 1992; 255-8.

  127.  Pazianas M, Phillips ME, Parfrey PS, Hutchinson TA.  Survival of patients treated with twice per week haemodialysis: a prognostically controlled study.  In: Prevention of Progressive Uremia, Ed E. Freidman.  Field & Wood, Inc.  Pennsylvania, USA, 1991; 54-7.

    Book

  128. Zaidi M, Pazianas M. Therapy of Osteoporosis. Cell Biology, Pharmacology and Drug Development.  Derwent Science Publishers, 1995 London.

     

    In Preparation

  129. Khairallah P, Nickolas T, Panagoutsos S, Pasadakis P, McCann F, Fraser W, Vargemezis V, Pazianas M.  Correlation between the Inflammatory and biochemical bone profile of patients on hemodialysis.